Eli Lilly (LLY) has abruptly halted the provision of discounts under the 340B Drug Pricing Program to certain U.S. hospitals that have failed to meet its data submission requirements. Lilly asserts that hospitals must share patient prescription and distribution information to prevent double-dipping and drug diversion. High-cost drugs such as Mounjaro (tirzepatide) and Trulicity (dulaglutide) are at the center of these restrictions. While the company frames this as a necessary step to ensure transparency, industry analysts suggest it is a strategic move to protect the pricing and profitability of its high-value products.

The American Hospital Association (AHA) and other major healthcare organizations have strongly protested these measures and have called on the Health Resources and Services Administration (HRSA) to intervene. Hospital groups argue that imposing data submission requirements for drug discounts without legal basis violates the 340B statute. As a result of this policy, vulnerable hospitals that support low-income populations now face significant financial challenges, as they must purchase Lilly's drugs at full wholesale acquisition cost (WAC) instead of the 20% to 50% discount. This raises concerns about reduced access to affordable medications for vulnerable populations.

The U.S. 340B discount drug market has grown to $66.3 billion in 2023, driven by hospital mergers and acquisitions and expanded pharmacy contracts, a 50% increase in two years. In addition to Eli Lilly, Novo Nordisk (NVO) has also begun to implement stricter data requirements to protect its profitability. Novo Nordisk is implementing similar policies for its diabetes and obesity products, including Wegovy (semaglutide). Industry analysts interpret these actions as a strategic effort to control the price decline of its leading products and mitigate the risk of margin erosion amid government pressure to lower drug prices.

The pharmaceutical industry previously attempted to transition to a rebate system that provided discounts after the fact, but the court ruled that changing the system without congressional approval was illegal. However, the newly elected Trump administration has shown a more flexible attitude toward introducing rebate pilot programs, increasing regulatory uncertainty. If regulatory agencies or federal courts ultimately uphold Eli Lilly's decision to suspend discounts, other major global pharmaceutical companies are likely to follow suit and require similar data submissions. This could lead to a significant shift in the U.S. healthcare supply chain, with hospitals facing reduced margins and major pharmaceutical companies gaining greater control over pricing.